CD274 and neoplasm: This discrepancy could be justified with the subgroups of the MB treated, but this detail is not reported in the original article (310) Also, using nivolumab in a little series of CNS tumors (with just one MB), it appears that a difference in the median survival was associated with the expression of PDL1 and high tumor mutation burden (311).